Targeting IGFR-1 and Insulin Receptor

    • Increased levels of IGF-1R are expressed in certain types cancer cells (e.g., prostate, pancreatic), which can lead to increased uptake of glucose from blood into tumor. However, IGF1R expression does not consistently correlate with disease control in heterogeneous groups of patients treated with anti-IGF1R mAbs.
    • IGF ligands (IGF1) levels have been shown to have predictive value in non–small-cell lung cancer (NSCLC) and sarcoma, but correlation between ligand level and tumor microenvironment has not been established.
    • In the presence of epidermal growth factor (EGF) inhibitors, IGF-1R can dimerize with EGFR, allowing pathway g to resume, leading to resistance of these inhibitors.
    Other topics in Molecular Targets and Pathways